Paltalk(PALT) - 2025 Q2 - Quarterly Report
2025-08-13 04:16
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number 001-38717 INTELLIGENT PROTECTION MANAGEMENT CORP. (Exact name of registrant as specified in its charter) | Delaware | 20-31918 ...
Armata Pharmaceuticals(ARMP) - 2025 Q2 - Quarterly Results
2025-08-13 04:16
Credit and Security Agreement Dated as of August 11, 2025 by and among ARMATA PHARMACEUTICALS, INC., as the Borrower, EACH SUBSIDIARY OF THE BORROWER HERETO FROM TIME TO TIME, as Guarantors, and INNOVIVA STRATEGIC OPPORTUNITIES LLC, as the Lender | TABLE OF CONTENTS | | --- | | Page | | --- | | ARTICLE I | DEFINITIONS; CERTAIN TERMS | 1 | | --- | --- | --- | | Section 1.01. | Definitions | 1 | | Section 1.02. | Terms Generally | 20 | | Section 1.03. | Accounting and Other Terms | 21 | | Section 1.04. | Time ...
VOC Energy Trust(VOC) - 2025 Q2 - Quarterly Report
2025-08-13 04:16
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the quarterly period ended June 30, 2025 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transition period from to Commission File Number: 001-35160 VOC ENERGY TRUST (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization ...
FTAC Emerald Acquisition Corp.(FLD) - 2025 Q2 - Quarterly Report
2025-08-13 04:16
比特币持有与投资 - 截至2025年6月30日,公司比特币投资国库持有1,492枚BTC,市场价值为1.598亿美元[172][187] - 公司比特币总持有量达1,579枚BTC,市场价值为1.692亿美元(基于2025年6月30日Coinbase收盘价107.2千美元/BTC)[186][187] - 比特币奖励国库(Rewards Treasury)持有87枚BTC,价值936.9万美元[187] - 800枚BTC因可转换票据抵押协议被限制使用[188] - 截至2025年6月30日,公司持有1,492枚比特币(价值1.599亿美元),其中800枚(价值8570万美元)作为可转换票据抵押品受限[275] - 比特币奖励库存87枚(价值940万美元)与客户奖励负债完全匹配[276] 融资与债务 - 2025年3月与SATS Credit Fund达成协议,发行可转换票据本金4630万美元,可转换为普通股(转换价12.5美元/股)并附带92.559万份认股权证(行权价15美元/股)[175] - 2025年6月签署2.5亿美元股权融资协议,资金拟用于比特币收购、营运资本等用途[178] - 公司持有8700万美元可转换票据,其中2025年3月票据(4630万美元)以500枚比特币作为抵押[277] - 可转换票据公允价值变动导致亏损530.96万美元,债务清偿损失为961.22万美元[226][242][243] - 可转换票据公允价值变动导致1184.4万美元损失,发行成本及费用达956.9万美元[262][263] - 债务清偿损失961.2万美元,含未摊销折扣及发行成本[264] 业务表现 - 2025年二季度平台月均交易额超8800万美元,累计历史交易总额突破30亿美元[190] - 2025年上半年新增超1万个账户,总账户数达61.5万;已验证账户数近8万[191] - 2025年2月宣布推出比特币奖励信用卡(Fold Credit Card),95%现有用户使用信用卡且85%用户认为比特币奖励功能至关重要[174] - 2025年5月推出比特币礼品卡(Fold Bitcoin Gift Card),计划年内扩展至线下零售渠道[176] - Fold+订阅服务年费为100美元或月费10美元[192] - 公司通过Fold借记卡交易赚取交换费,费率由Visa设定,具体比例因交易类型和商户类别等因素而异[192] - 交易费用包括即时转账费、国际交易费和ATM费,按交易金额百分比或固定金额收取[192] - 商户优惠收入受季节性影响,第四季度和亚马逊Prime日等购物高峰期收入较高[193] - 比特币交易收入包括交易费(如1.5%的买卖金额)和价差收益[195] - 比特币礼品卡收入计入总收入和销售成本,公司作为交易主体确认收入和成本[196] - 营销奖励和收入奖励按比特币公允价值计入负债,未赎回前按市价调整[201] - 奖励需满足30天结算期方可赎回,以防止欺诈活动[200] - 公司根据历史数据和用户趋势预估奖励到期情况,并相应计提[204] 财务数据关键指标变化(收入与利润) - 2025年第二季度净收入为817.59万美元,同比增长59%(3,037,302美元)[226][228] - 银行和支付业务收入为792.16万美元,同比增长55%(2,800,987美元),主要受商户优惠收入增长61%驱动(从460万美元增至750万美元)[227][229] - 托管和交易收入从2024年的1.93万美元增至2025年的24.16万美元,增幅显著[227][231] - 公司2025年上半年净收入为1526.4万美元,同比增长52%(52%)[245][247] - 银行和支付业务收入增长48%至1484.3万美元,主要受商户优惠收入增长53%驱动(从910万美元增至1390万美元)[246][248][249] - 托管和交易收入从2024年名义金额增至2025年39.3万美元,比特币礼品卡新产品贡献初期收入[250][251] 财务数据关键指标变化(成本与费用) - 运营费用总额从632.76万美元增至1,450.14万美元,同比增长129%(8,173,840美元)[226] - 薪酬和福利费用从84.93万美元增至367.67万美元,同比增长333%(2,827,377美元),员工人数从22人增至43人[226][236] - 营销费用从2024年的3.83万美元增至2025年的62.09万美元,主要用于推广新产品[226][238] - 专业费用从23.89万美元增至127.03万美元,同比增长432%(1,031,483美元),主要因上市相关合规成本增加[226][239] - 银行和支付成本同比增长53%至1444.2万美元,与商户优惠量增长直接相关[245][252] - 员工人数从2024年22人增至2025年43人,薪酬福利费用达1013.5万美元(含690万美元股权薪酬)[255][256] - 营销费用同比大幅增至102.1万美元,用于支持新产品发布[257] - 专业费用增至305.9万美元,主要因上市相关法律及合规支出[258] 比特币价格波动影响 - 比特币价格从2024年6月的6.27万美元升至2025年6月的10.72万美元,推动客户奖励负债和数字资产-奖励国库的未实现收益变化[240][241] - 数字资产-投资国库的未实现收益为3,658.22万美元,而2024年同期亏损110.61万美元,主要受比特币价格波动影响[226][241] - 比特币价格波动影响:客户奖励负债录得60%收益(970.6万美元),投资国库比特币资产实现2096.5万美元收益[259][261] - 数字资产投资的公允价值变动计入非营业收入或费用[217] 财务健康与现金流 - 2025年第二季度调整后EBITDA为-469万美元,同比下降301%(3.5百万美元)[270] - 2025年上半年调整后EBITDA为-889.9万美元,同比下降340%(6.9百万美元),主要驱动因素包括专业费用增加280万美元、薪酬福利(不含股权激励)增加160万美元[271][283] - 公司现金及等价物为660万美元,营运资本为正780万美元,但累计赤字达1.368亿美元[274] - 2025年上半年经营活动现金净流出895万美元,同比增加773万美元,主要因利息支出增加324万美元及专业费用增加280万美元[282][283] - 2025年上半年投资活动现金流出281万美元,主要因比特币库存增加[285] 风险管理与估值 - 公司采用市场法中的可比公司方法进行估值,涉及收入、息税前利润、息税折旧摊销前利润、净利润及/或有形账面价值等财务指标[295] - 比特币市场价格波动对公司收益及比特币计价资产和负债的账面价值可能产生重大影响[299] - 公司部分资产和负债以比特币计价,包括比特币投资国库、客户奖励负债和2025年3月投资者票据[299] - 比特币的监管环境(包括法律地位、会计和税务处理)将显著影响其增长[300] - 机构投资者(如对冲基金、共同基金、企业和国家)的参与可提升市场信心和流动性[300] - 货币政策(如利率和货币供应)可能影响比特币的采用,低利率和货币贬值政策常推动对比特币等替代投资的需求[300] - 技术进步(如区块链可扩展性提升和安全性增强)可能促进比特币的采用和金融系统整合[300] - 会计估计涉及重大不确定性和判断,假设变化可能显著改变公司财务状况和结果的财务呈现[297] - 比特币的市场价格风险是公司市场风险暴露的主要因素[298] - 公司财务结果可能因比特币公允价值调整而出现波动[299]
FTAC Emerald Acquisition (EMLD) - 2025 Q2 - Quarterly Report
2025-08-13 04:16
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 001-41168 Fold Holdings, Inc. (Exact Name of Registrant as Specified in its Charter) | Delaware | 86-2170416 | | ...
FTAC EMERALD ACQ(EMLDU) - 2025 Q2 - Quarterly Report
2025-08-13 04:16
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 001-41168 Fold Holdings, Inc. (Exact Name of Registrant as Specified in its Charter) | Delaware | 86-2170416 | | ...
FTAC Emerald Acquisition Corp.(FLDDU) - 2025 Q2 - Quarterly Report
2025-08-13 04:16
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 001-41168 Fold Holdings, Inc. | Delaware | 86-2170416 | | --- | --- | | ( State or other jurisdiction of | (I.R. ...
Novume(REKR) - 2025 Q2 - Quarterly Report
2025-08-13 04:16
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 Delaware 81-5266334 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to ________ ...
Lineage Cell Therapeutics(LCTX) - 2025 Q2 - Quarterly Report
2025-08-13 04:16
UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to ________ Commission file number 001-12830 Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 Lineage Cell Therapeutics, Inc. (Exact name of registrant as specified in its charter) California 94-3127919 | Titl ...
Lyra Therapeutics(LYRA) - 2025 Q2 - Quarterly Results
2025-08-13 04:16
Exhibit 99.1 Lyra Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update – Positive ENLIGHTEN 2 Phase 3 results announced in June 2025 propel business activities in manufacturing, regulatory strategy and ENLIGHTEN clinical dataset analysis to advance path forward for LYR-210 for treatment of chronic rhinosinusitis (CRS) – – Financing announced in June 2025 extends cash runway into 3Q 2026 – WATERTOWN, Mass., August 12, 2025 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasda ...